Abstract: The invention relates to compounds of Formula (I) and their use as selective pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
Abstract: The invention relates to compounds of Formula (I) and their use as selective dipeptidyl peptidase I inhibitors, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
Abstract: The invention relates to compounds of Formula (I) and their use as selective dipeptidyl peptidase I inhibitors, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
Abstract: The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.
Type:
Grant
Filed:
September 6, 2001
Date of Patent:
June 15, 2010
Assignee:
Prozymex A/S
Inventors:
Johan Gotthardt Olsen, Anders Kadziola, Søren Weis Dahl, Connie Lauritzen, Sine Larsen, John Pedersen, Dusan Turk, Marjetka Podobnik, Igor Stern
Abstract: A monoacyl semicarbazide of the general formula (I): (I), or a pharmaceutically acceptable salt or ester thereof, is capable of selectively inhibiting dipeptidyl-peptidase I (DPP-I), also known as cathepsin C. A compound of the invention is useful as an active substance for the treatment of inflammation, type 2 diabetes, asthma, severe influenza, respiratory syncytial virus infection, CD8 T cell inhibition, inflammsatory bowel diseases, psoriasis, atopic dermatitis, Papillon Lefevre syndrome, Haim Munik syndrome, gum disease, periodontitis, rheumatoid arthritis, Huntington's disease, Chaga's disease, Alzheimer's disease, sepsis or for application in target cell apoptosis.
Type:
Application
Filed:
May 27, 2004
Publication date:
July 5, 2007
Applicant:
ProZymex A/S
Inventors:
Jon Bondebjerg, Henrik Fuglsang, Lars Naerum
Abstract: A peptidyl nitrile of the general formula (I) or a pharmaceutically acceptable salt or prodrug thereof, is capable of selectively inhibiting dipeptidyl-peptidase (DPP-I), also known as cathepsin C. A compound of the invention is useful as an active substance for the treatment of inflammation, type 2 diabetes, asthma, severe influenza, respiratory syncytial virus infection, CD8 T cell inhibition, inflammatory bowel diseases, psoriasis, atopic dermatitis, Papillon Lefevre syndrome, Haim Munk syndrome, gun disease, periodontitis, rheumatoid arthritis, Huntington's disease, Chagas' disease, Alzheimer's disease, sepsis or for application in target cell apoptosis.
Type:
Application
Filed:
June 17, 2004
Publication date:
May 3, 2007
Applicant:
ProZymex A/S
Inventors:
Jon Bondebjerg, Henrik Fuglsang, Lars Naerum